Fact CheckerSign in

NCT07631143Not yet recruitingPhase 1/2

Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With MS

Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With Multiple Sclerosis

Source: ClinicalTrials.gov · Last updated 5 Jun 2026

Brief summary (registry, in English)

This study will look at the safety, tolerability and feasibility of a non-invasive treatment called Acute Intermittent Hypoxia (AIH) in people with Multiple Sclerosis (MS) at different stages of the disease course.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
9 (estimated)
First submitted
13 May 2026
Start date
1 Jul 2026
Primary completion date
1 Aug 2028
Lead sponsor
University of Saskatchewan
NCT number
NCT07631143

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 9
  • From 1 Jul 2026 to the primary completion date, 1 Aug 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Any of the following documented respiratory disorders: obstructive sleep apnea, chronic obstructive pulmonary disease, uncontrolled asthma, hypoxic pulmonary disease, respiratory infection in the previous 3 months

Other illness

  • Ischemic cardiac disease
  • Cardiac arrhythmia
  • Severe hypertension (\>160/100)
  • Seizure disorders

Other

  • Pregnancy
  • Medically unstable in another capacity
  • Unable to provide informed consent

Who the study is looking for

  • \-
  • Group 1:
  • People with a confirmed diagnosis of MS and advanced disability level (Expanded Disability Status Scale (EDSS) \>6.5 and \<9)
  • Without relapse for at least 90 days prior
  • Older than age 18
    • Group 2:
  • People with a confirmed diagnosis of relapsing remitting MS
  • Acute disabling relapse onset within the past 4 weeks. A disabling relapse will be defined as at least 1.0-point increase on the EDSS.
  • Older than age 18
    • Group 3:
  • People with a confirmed diagnosis of MS that is non-active and progressive (Primary or Secondary Progressive MS). Non-active will be defined as without MS relapse, new/enlarging or enhancing MRI lesions within the past 1 year.
  • EDSS \<=6.5
  • Older than age 18

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.